Literature DB >> 8308864

Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.

M P Hay1, W R Wilson, J W Moselen, B D Palmer, W A Denny.   

Abstract

A series of novel bis(nitroimidazolyl)alkanecarboxamides has been prepared and evaluated for hypoxia-selective cytotoxicity and hypoxic cell radiosensitisation in vitro and in vivo. The compounds were prepared by direct coupling of preformed side chain acid and amine components, using diethyl phosphorocyanidate at room temperature. Although designed to be bis-bioreductive prodrugs of DNA cross-linking agents, none of the compounds showed evidence of DNA cross-linking activity, being equally potent against cell lines deficient and proficient in repair of cross-links. However, one of these compounds, N-[2-(2-methyl-5-nitro-1H-imidazolyl)ethyl]-4-(2-nitro-1H- imidazolyl)butanamide (10; SN 24699), showed high hypoxic selectivity as a cytotoxin (rising to 200-fold after exposure to the drug for several hours) in the repair-proficient Chinese hamster cell line AA8. This selectivity was greater than observed for the alkylating 2-nitroimidazole (4; RB 6145) (40-fold) or simple mononitroimidazoles (5-25-fold). Investigation of structure-activity relationships for hypoxic selectivity of bis(nitroimidazoles) was restricted by their low aqueous solubility, but a certain minimum separation of the two nitroimidazole units (by more than five atoms) appears desirable. All the compounds radiosensitized hypoxic cells in vitro but were little more potent as radiosensitizers than the corresponding monomeric nitroimidazoles. Compound 10 caused additional cell killing in the KHT tumor when multiple drug doses were administered in combination with a single dose of radiation. It is not yet clear whether this activity reflects hypoxic cell radiosensitization or cytotoxicity toward hypoxic cells, but this new class of bis-bioreductive agent clearly warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8308864     DOI: 10.1021/jm00029a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole.

Authors:  D J Yang; S Ilgan; T Higuchi; F Zareneyrizi; C S Oh; C W Liu; E E Kim; D A Podoloff
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Authors:  Paul D Bonnitcha; Simon R Bayly; Mark B M Theobald; Helen M Betts; Jason S Lewis; Jonathan R Dilworth
Journal:  J Inorg Biochem       Date:  2009-10-24       Impact factor: 4.155

3.  Synthesis and characterization of a hypoxia-sensitive MRI probe.

Authors:  Federico A Rojas-Quijano; Gyula Tircsó; Enikő Tircsóné Benyó; Zsolt Baranyai; Huan Tran Hoang; Ferenc K Kálmán; Praveen K Gulaka; Vikram D Kodibagkar; Silvio Aime; Zoltán Kovács; A Dean Sherry
Journal:  Chemistry       Date:  2012-06-27       Impact factor: 5.236

4.  Novel 99mTc labelled complexes with 2-nitroimidazole isocyanide: design, synthesis and evaluation as potential tumor hypoxia imaging agents.

Authors:  Qing Ruan; Xuran Zhang; Xiao Lin; Xiaojiang Duan; Junbo Zhang
Journal:  Medchemcomm       Date:  2018-05-07       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.